



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096. Telangana. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1402
CIN : L24239AP1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 10th August, 2016

To,
The Managers,
Corporate Filings Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Managers,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Subject: Outcome of the Board Meeting held on 10th August, 2016.

Dear Sir/Madam,

Pursuant to the Regulation 33 & 47 read with the Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letter dated 1st August, 2016 we would like to inform you that the Board of Directors of the Company at their meeting held on today, have approved the following:

1. Unaudited Standalone financial results for the Quarter ended on 30th June, 2016
2. Directors' Report for Financial Year 2015-16
3. Notice of the 28th Annual General Meeting.
4. Fixed Record date as 20th August, 2016 for ascertaining the members eligible for receiving the Annual Report for the Financial Year 2015-16.
5. Fixed the Book Closure dates from 24th September, 2016 to 30th September, 2016 (both days inclusive) for ascertaining the members eligible for receiving the dividend.

The agenda item relating to consideration of Draft scheme of Demerger could not be transacted in this meeting and it was decided by the Board to adjourn the meeting to Saturday, the 13th August, 2016 at 03:00p.m. to have a detailed discussions on the matter.

We are enclosing herewith the unaudited financial results for the quarter ended on 30th June, 2016 as approved by the Board along with the Limited Review Report.

Please take the above intimation on your records.

Yours Faithfully,

For SMS Pharmaceuticals Limited


Saurav Roy
Company Secretary



SMS PHARMACEUTICAL LIMITED


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096
Statement of Un-Audited Financial Results for the Quarter Ended 30th June, 2016

S.No.	Particulars	Quarter Ended		Year Ended	
		30-06-2016	30-06-2015	31-03-2016	31-03-2016
		(Unaudited)	(Unaudited)	(Unaudited)	Audited
1	Income from Operations				
	(a) Net sales/Income from Operations	13,737.01	11,301.88	15,722.39	55,607.10
	(b) Other Operating Income	848.13	1,093.32	1,458.37	4,712.23
	Total Income from Operations (net)	14,585.14	12,395.20	17,180.76	60,319.34
2	Expenses				
	(a) Cost of materials consumed	10,311.10	8,123.97	10,639.05	39,945.32
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	(1,229.37)	(256.77)	443.72	(963.93)
	(d) Employee Benefits Expense	1,010.80	882.02	1,090.40	3,811.31
	(e) Depreciation and amortisation expense	611.88	465.26	523.81	1,943.30
	(f) Other expenses	2,091.52	1,883.46	2,574.76	8,607.08
	Total - (a to f)	12,795.93	11,097.94	15,271.74	53,343.08
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1) - (2)	1,789.21	1,297.25	1,909.02	6,976.25
4	Other Income	31.19	70.37	86.47	360.79
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3)+(4)	1,820.40	1,367.62	1,995.49	7,337.05
6	Finance costs	560.95	447.83	451.67	1,709.81
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5)-(6)	1,259.44	919.79	1,543.82	5,627.24
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before Tax (7)+(8)	1,259.44	919.79	1,543.82	5,627.24
10	Tax Expenses	344.14	200.00	250.99	1,463.32
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	915.30	719.79	1,292.84	4,163.92
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)	-	-	-	-
13	Net Profit / (Loss) for the period (11) - (12)	915.30	719.79	1,292.84	4,163.92
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority Interest*	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	915.30	719.79	1,292.84	4,163.92
17	Paid-up equity share capital Rs.1/- per share	915.30	719.79	1,292.84	4,163.92
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	84,652,030	84,652,030	84,652,030	84,652,030
19.i	Earning Per Share (before extraordinary items) (of Rs. 1 / each) (not annualised)	1.08	0.85	1.53	4.92
19.ii	Earning Per Share (after extraordinary items) (of Rs. 1/ each) (not annualised)	1.08	0.85	1.53	4.92



PARTICULARS OF SHARE HOLDING					
1	Public Shareholding - Number of Shares - Percentage of Shareholding	30,579,180 36.12	3,054,760 36.09	30,579,180 36.12	30,579,180 36.12
2	Promoters and Promoters Group Shareholding** a) Pledged/Encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company) b) Non-encumbered - Number of Shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of Shares (as a % of the total share capital of the company)	- - - 54,072,850 100 63.88	- - - 5,410,443 100 63.91	- - - 54,072,850 100.00 63.88	- - - 54,072,850 100 63.88

Particulars		3 Months ended 30-06-2016	
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter		Nil
	Received during the quarter		Nil
	Disposed of during the quarter		Nil
	Remaining unresolved at the end of the quarter		Nil

Notes:	
1	The above results were reviewed by the Audit Committee on 8th August, 2016 and taken on record by the Board of Directors at its meeting held on 10th August, 2016 and "Limited Review" of the same has been carried out by the Statutory Auditors of the company.
2	The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.
3	The Company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4	During the 3rd quarter of 2015-16, the equity shares having face value of Rs.10/- each has been sub-divided into Rs.1/- each, accordingly the number of shares and earnings per share for the previous period/quarters have been restated
5	Tax expenses for the quarter ending 30.06.2016 of Rs.334.14 Lakhs includes deferred tax liability amount of Rs.74.14 Lakhs
6	Figures of previous periods have been regrouped / rearranged wherever necessary.
	Place: Hyderabad
	Date : 10-08-2016
	By Order of the Board for SMS Pharmaceuticals Limited  Ramesh Babu Potluri Chairman & Managing Director

Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED for the quarter ended 30th June 2016. The statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015") which has been initialized by us for identification purposes. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting standards, prescribed under Sec.133 of Companies Act, 2013, read with rule 7 of the companies (Accounts) Rules, 2014 and Accounting standard 30, Financial Instruments. Recognition and Measurement issued by the Institute of Chartered Accountants of India to the extent it does not contradict any other accounting standard referred to in section 133 of the companies Act read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 10-08-2016

For **RAMBABU & CO.,**
Chartered Accountants
Reg. No. 002976S



RAVI RAMBABU
Partner
M. No. 018541

